Question explored with the scientific record
what is know to help with symptoms of menopose or postpone it
The best evidence points to menopausal hormone therapy (MHT) as the most effective option for symptom relief, but the evidence on delaying menopause is absent from this retrieval.
The retrieved evidence consistently shows that MHT, particularly systemic estrogen, is the most effective treatment for hot flashes and night sweats. One review reports an up to 80% decrease in these symptoms, with peak effect by about 4 weeks [1]. A 2025 review calls MHT the "gold standard" for managing vasomotor symptoms, mood disturbances, and sleep disruption [2]. A small 2026 study of 60 premenopausal women found 91.7% reported symptom relief from hormone replacement therapy [3]. These results come from narrative reviews and a small descriptive study, not large, long-term randomized trials with hard endpoints like all-cause mortality.
The evidence does not support any intervention to postpone menopause. None of the retrieved studies tested whether any treatment delays the onset of menopause itself. The question of postponement is simply not addressed in this literature.
The risks of MHT are real and depend on the regimen, route, and the woman's age. The Women's Health Initiative found that combined estrogen/progestin therapy increased breast cancer risk (hazard ratio 1.3, or about 8 extra cases per 10,000 users per year), while estrogen alone was linked to fewer breast cancers (hazard ratio 0.77) [1]. Venous thromboembolism risk also increased, especially in older women and those with higher BMI [1]. Transdermal estrogen appears to carry a lower risk of blood clots than oral estrogen, based on observational data [4]. The evidence is clear that MHT helps symptoms but carries trade-offs that must be weighed individually.
My call: MHT is effective for symptom relief, but no evidence here shows it postpones menopause. Confidence in symptom relief is moderate; confidence in any effect on postponement is not clear, because the question was never studied in these records.
Sources used 4
-
Confronting the challenges of the menopausal transition
For most recently menopausal women, menopausal hormone therapy effectively relieves vasomotor symptoms and its benefits outweigh risks, while risks such as VTE, breast cancer, and cardiovascular events depend on age, time since menopause, BMI, and regimen.
DOI: 10.1186/s40695-015-0008-5 -
Menopausal Hormone Therapy: Clinical Guidance for Symptom Relief and Genitourinary Management
Menopausal hormone therapy remains the gold standard for managing vasomotor symptoms, mood disturbances, sleep disruption, and genitourinary syndrome of menopause when tailored to individual risk profiles, with route, dose, and progestin use individualized through shared decisio…
DOI: 10.36348/sijog.2025.v08i07.006 -
HORMONE REPLACEMENT THERAPY AMONG PRE-MENOPAUSAL WOMEN PATIENTS WITH SEVERE MENOPAUSAL SYMPTOMS
A descriptive study of 60 premenopausal women aged 45-50 found that 91.7% reported symptom relief from hormone replacement therapy, though quality-of-life improvement was less pronounced (41.7%) and most participants were overweight or obese.
DOI: 10.17654/2347527726002 -
The safety of oral versus transdermal estrogen
This Practice Pearl compares safety of oral versus transdermal estrogen, concluding that transdermal estrogen has lower VTE, stroke, and cardiovascular risk in high-risk women, while average-risk younger postmenopausal women have not shown increased risk with low-dose oral estro…
DOI: 10.1097/gme.0000000000001636